Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzhe ...

Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a ...

The Food and Drug Administration’s (FDA) approval of the first blood test to aid in the diagnosis of Alzheimer’s disease ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic (IVD) test for evaluating amyloid ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, making the test the first to get signoff to aid in the early detection of the ...

Fujirebio's test works with the company's Lumipulse equipment, which the company says is already "widely available in clinical laboratories" around the U.S. Fujirebio describes Lumipulse as a ...

The Lumipulse blood test is made by Japanese company, Fujirebio Diagnostics, which markets a similar Alzheimer's test that measures cerebrospinal fluid collected by spinal tap. The company did not ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...

—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearance for Patients Being Assessed for Alzheimer’s Disease. — —Availability of Accurate, Accessible, Blood-Based Diagnostic ...

(BUSINESS WIRE )--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in ...